Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - 2012
Newron and Zambon enter into a strategic collaboration and licence agreement for Safinamide14/05/2012 | 
ENG
| 
GER
| |
Newron Reports Completion of Phase III program for Safinamide in early and advanced Parkinsons disease patients14/05/2012 |
ENG
|
GER
| |
Newron Announces change in Management14/05/2012 |
ENG
|
GER
| |
Newron and Zambon extend option period for strategic collaboration and licence agreement for Safinamide in the EU and US to May 13 201202/05/2012 |
ENG
|
GER
| |
Newron and Zambon enter into strategic collaboration and licence option for Safinamide05/04/2012 |
ENG
|
GER
| |
Newron announces financial calendar for 201229/02/2012 |
ENG
|
GER
| |
Newron signs license agreement with Meiji Seika Pharma for safinamide covering Japan and key Asian territories14/02/2012 |
ENG
|
GER
| |
Newron to grant safinamide license to Meiji Seika Pharma for Japan and key Asian territories05/01/2012 |
ENG
|
GER
|